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Disturbances in the development 
and function of blood- or lymphatic 
vasculature are involved in many 
diseases. Vascular endothelial 
growth factors are central mediators 
in vascular development. In this 
thesis, a lentiviral perivitelline 
transgenesis method was used 
to study the role of VEGF-D in 
cardiovascular diseases, ischemic 
conditions and tumor formation. It 
clarifies the function of VEGF-D in 
angiogenesis and shows a potential 
use as a treatment in tissue ischemia. 
However, unregulated long-
term expression promoted tumor 
formation.
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ABSTRACT 
 
The aim of this work was to study the role of vascular endothelial growth factor (VEGF)-D 
in cardiovascular diseases and ischemic conditions. A secondary aim was to evaluate the 
potential role of VEGF-D in tumor formation. Transgenic (TG) and knockdown (KD) 
models were used to study VEGF-D function in mice. 
Disturbances in vascular or lymphatic development and function may be involved in a 
variety of diseases. VEGFs are central mediators in the development and the maintenance 
of blood and the lymphatic vasculature. Five mammalian VEGFs have been identified, 
VEGF-A, -B, -C, -D and placental growth factor (PlGF), all of them having distinct binding 
properties to their receptors VEGFR-1, -2 and -3. VEGFs are known to be upregulated in 
tumors, where they remodel the tumoral vasculature. VEGF-D contributes to the growth 
and formation of blood- and lymphatic vessels by binding to both VEGFR-2 and -3. 
Lentiviral constructs with ubiquitous and endothelial specific promoters were used to 
overexpress VEGF-D in mice. In addition, a construct with a small hairpin RNA (shRNA) to 
silence VEGF-D was used. The lentiviral perivitelline injection method was used to produce 
TG and KD mice. Founder mice positive for the VEGF-D transgene were born and they 
were further bred and studied for up to five generations. Littermates lacking the transgene 
were used as controls. Hindlimb ischemia was induced to study the role of VEGF-D in 
angiogenesis and in the recovery from ischemic injury. 
The perivitelline transgenesis method was very efficient, since there were several TG-
positive founders. The transgene was expressed in various tissues, with differing 
expression levels between the mouse lines. The expression level was starting to fade in 
consecutive generations. Increased capillary density was observed in the skeletal muscle 
and myocardium of the ubiquitously expressing mice. The mice also showed improved 
muscle regeneration after ischemia, but no changes were observed in the lymphatic system. 
However, increased tumor formation was found in both overexpressing mouse lines, which 
significantly decreased their lifespan. In the ubiquitously VEGF-D expressing TG mice, the 
tumors were mainly breast adenocarcinomas. In the shVEGF-D mice, the transgene was 
effectively silenced in all studied tissues. These mice had a phenotype which displayed 
variable pathological conditions. This may be attributable to the widespread effects of 
expressed shRNA, which disturbs the endogenous micro RNA (miRNA) machinery. 
In conclusion, VEGF-D may be effective in the treatment of tissue ischemia. However, 
unregulated long-term expression may be harmful by promoting malignant transformation. 
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TIIVISTELMÄ 
 
Tutkimuksen tarkoituksena oli tutkia VEGF-D:n merkitystä sydän- ja verisuonisairauksissa 
sekä kudosiskemiassa. Halusimme myös tutkia VEGF-D:n merkitystä kasvainten 
muodostuksessa. VEGF-D:n toimintaa tutkittiin siirtogeenisten ja hiljennettyjen hiirimallien 
avulla.  
Veri- ja imusuonten kehityksen tai toiminnan häiriöt voivat altistaa monille eri 
sairauksille. Verisuonen endoteelin kasvutekijät (VEGF) ovat keskeisiä tekijöitä veri- ja 
imusuonten kasvussa ja muokkauksessa. Nisäkkäiltä on löydetty viisi eri VEGF 
kasvutekijää, VEGF-A, -B, C, -D sekä istukan kasvutekijä (PlGF), jotka sitoutuvat eri tavoin 
VEGFR-1, -2 ja -3 reseptoreihin. Kasvaimet ilmentävät runsaasti VEGF:iä ja ne muokkaavat 
aktiivisesti kasvaimen verisuonistoa. VEGF-D sitoutuu VEGFR-2 ja -3 reseptoreihin ja 
osallistuu veri- ja imusuonten kasvuun sekä muokkaukseen. 
Lentiviruskonstrukteja, joissa hyödynnettiin yleisesti ilmentävää sekä endoteelispesifistä 
promoottoria, käytettiin ilmentämään VEGF-D:tä hiirillä. Hiljennetty VEGF-D hiirimalli 
(shVEGFD) luotiin shRNA:n avulla. Siirtogeeniset hiiret sekä hiljennetty hiirimalli luotiin 
lentivirusten perivitelliini-injektio-menetelmällä. Siirtogeenin suhteen positiiviset 
kantahiiret paritettiin edelleen ja tutkittiin viiden sukupolven ajan. Kontrollieläiminä 
käytettiin siirtogeenin suhteen negatiivisia hiiriä. Alaraajaiskemiamallin avulla selvitettiin 
VEGF-D:n merkitystä angiogeneesissä sekä iskeemisen vaurion paranemisessa. 
Perivitelliinitransgeneesi oli erittäin tehokas menetelmä, koska TG-positiivisten 
kantahiirten määrä oli korkea. Siirtogeeniä ilmennettiin monissa eri kudoksissa, mutta 
ilmentymistasot vaihtelivat hiirilinjojen välillä. Sukupolvien edetessä siirtogeenin 
ilmentyminen vähentyi. Yleisilmennettävällä hiirimallilla hiussuonten määrä oli lisääntynyt 
luurankolihaksissa sekä sydänlihaksessa. Myös lihasten toipuminen iskeemisestä vauriosta 
nopeutui, mutta imusuonistossa ei havaittu muutoksia. Molemmilla yli-ilmentävillä 
hiirimalleilla havaittiin lisääntynyttä tuumorimuodostusta, joka lyhensi merkittävästi 
eläinten elinikää. Yleisesti yli-ilmentävien hiirien kasvaimista suuri osa oli rintarauhasen 
adenokarsinoomia. Hiljennetyllä hiirimallilla VEGF-D oli hiljennetty tehokkaasti kaikissa 
tutkituissa kudoksissa. Näillä hiirillä oli epäspesifinen fenotyyppi ja vaihtelevia patologisia 
muutoksia. Tämä voi johtua ilmennetyn shRNA:n laaja-alaisesta vaikutuksesta, joka 
häiritsee hiiren omaa miRNA mekanismia. 
Väitöskirjatyössä osoitettiin, että VEGF-D voi olla tehokas iskemian hoidossa. 
Säätelemätön pitkäaikainen ilmentyminen voi olla kuitenkin haitallista edistämällä 
pahanlaatuisia muutoksia elimistössä. 
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1 Introduction  
The vascular system can be differentiated into four types of vessels; arteries, veins, 
capillaries and lymphatic vessels. The heart pumps oxygen rich blood via arteries to 
the capillaries, where oxygen and nutrients diffuse to tissues. The blood flows from 
arteries to capillaries and then through veins back to the heart. The arteries control 
the blood pressure and blood flow by contracting and dilating, although veins can 
also participate in the maintenance of blood pressure by storing and releasing large 
volumes of blood. The lymphatic system collects excess fluids from cells, transfers it 
back to the blood circulation and it also delivers cells of the immune system. The 
formation, development and stabilization of the blood- and lymphatic vascular 
system is maintained to a large extent by vascular endothelial growth factors 
(VEGFs). Five different mammalian VEGFs have been found, which bind to their 
VEGF receptors (VEGFR) signaling for growth and maintenance of blood or 
lymphatic vessels (Ellis, Hicklin 2008).  
Inadequate blood flow causes tissue ischemia which may clinically manifest itself 
as claudication, which may lead to amputation of lower limbs, transient ischemic 
attack or stroke in the brain and angina or myocardial infarction in the heart 
depending on the severity and location of the perfusion deficit. In tumors, VEGFs 
restructure the vasculature and in this way they can promote malignant growth 
(Ellis, Hicklin 2008). Anti-angiogenic therapies such as bevacizumab (humanized 
anti-VEGF antibody), are already approved in the treatment of metastatic breast-, 
colorectal-, ovarian-, kidney- and lung cancer (Rossari et al. 2012, Bates et al. 2012, 
Banerjee, Kaye 2012, Lambrechts et al. 2012, Sandler et al. 2006). 
Therapeutic angiogenesis is a promising treatment for ischemic conditions and 
lymphatic diseases (Yla-Herttuala 2009). In clinical trials, therapeutic angiogenesis 
has been proved to be relatively safe (Hedman et al. 2003, Hedman et al. 2009). 
However, some concerns have been raised from results emerging from animal 
studies, such as tissue edema, inflammation, fibrosis, vessel instability, excessive 
vessel growth and tumors (Rutanen et al. 2004, Korpisalo et al. 2008a, Markkanen et 
al. 2005). Proangiogenic treatment may exert harmful effects in atherosclerosis or 
diabetes, since it may accelerate disease progression. 
During the last decade, vascular growth factors have received increased attention 
in biomedical studies. VEGF-D is a relatively new member of the VEGF family and 
its exact role in vivo is still largely unclear. In this thesis, the role of VEGF-D was 
studied in vivo using transgenic (TG) and knockdown (KD) mice generated using 
lentiviral techniques. It was found that overexpressed VEGF-D caused malignant 
tumors when expressed ubiquitously or in the endothelium. The KD of VEGF-D 
evoked a variety of pathologies pointing to a more diverse effect not only of the 
silenced gene but perhaps also of the used short hairpin (sh) RNA-RNA interference 
(RNAi) system. 
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2 Review of the literature  
2.1 VASCULAR SYSTEM 
2.1.1 Growth and organization 
The cardiovascular system in vertebrates is the first functional structure to develop 
during embryogenesis. The heart pumps blood via vessels and the circulation plays 
many crucial roles in the body; oxygen and nutrient delivery to cells, waste disposal, 
hormonal traffic and also transfer of immune responses. A functional circulatory 
system is essential for providing sufficient oxygen and nutrients to the developing 
embryo. The system differentiates into arterial, venous and lymphatic vessels (Risau, 
Flamme 1995, Rossant, Howard 2002). 
During early development, the heart starts to pump which produces a high-
pressured blood flow through the arterial vessels. The arterial vessels have a large 
diameter to allow large blood volumes and smooth muscle cells (SMCs) and 
extracellular matrix (ECM) components to support the vessel wall. Blood flows back 
to the heart through veins, which have a lower pressure than the arteries. Veins have 
valves to prevent the backflow of blood. Previous studies have shown that these 
hemodynamic differences direct the specification of blood vessels (Riha et al. 2005, 
Ando, Yamamoto 2009). Other studies demonstrate different molecular signals in 
arteries and veins from the early stages of development. Small capillaries can also be 
distinguished based on their molecular markers. These markers are proteins 
involved in regulating the initial step in differentiation of arteries and veins (Wang, 
Chen & Anderson 1998, Yancopoulos, Klagsbrun & Folkman 1998, Torres-Vazquez, 
Kamei & Weinstein 2003). 
2.1.2 Vasculogenesis 
Early blood vessels are formed by vasculogenesis when endothelial precursor cells 
(angioblasts) differentiate and form a network of new capillaries (Figure 1). This 
event starts when a group of cells grows and starts to experience a lack of oxygen. 
This causes the cells to produce hypoxia-related signals and initiates vascular 
growth. The process is complex including a variety of regulatory mechanisms such 
as the VEGF/VEGFR and angiopoietin (Ang)/Tie -pathways (Carmeliet 1996, Ferrara 
1996, Ferrara 1999, Shalaby 1995). Also Ephrin (Eph) / Eph receptor (Gale, 
Yancopoulos 1999) and Delta/Notch pathways, platelet derived growth factor 
(PDGF), fibroblast growth factors (FGF) (Zhou et al. 1998, Lindahl et al. 1998) and 
transforming growth factor beta (TGF-β) (Dickson et al. 1995) have important roles 
in the vascular development. However, the major regulators of the formation of 
vasculature are VEGF–A and delta-like ligand 4 (Dll4) (Shutter et al. 2000, Lobov et 
al. 2007). 
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Figure 1. Formation of primary vascular plexus from angioblasts (vasculogenesis) and 
further development into a mature vascular system via different forms of angiogenesis 
and arteriogenesis (Korpisalo, Yla-Herttuala 2010). 
2.1.3 Angiogenesis 
Angiogenesis is defined as the growth of new blood vessels, which can happen in 
three main ways: sprouting, intussusception and elongation (Figure 1). Circulating 
endothelial cells (EC) can also be incorporated into vessel walls (Chung, Ferrara 
2011). New vascular sprouts are formed from pre-existing vessels. Quiescent ECs are 
activated by an angiogenic stimulus; they start to produce proteases, which open the 
basal lamina and the surrounding tissue allowing the sprouts to grow. Eventually 
the sprouts meet and connect (anastomosis), creating a closed tubular system. The 
mature network of vessels differentiates into arteries and veins. During 
embryogenesis before a complete circulation this maturation process is regulated by 
signaling molecules such as VEGF, Notch and Eph-B2 (Salvucci et al. 2009, Coultas, 
Chawengsaksophak & Rossant 2005). However, when the blood is circulating, 
laminar and shear stress partly regulate the arterial/vein differentiation (Shutter et 
al. 2000, Lawson et al. 2001, Swift, Weinstein 2009). 
In sprouting angiogenesis, new capillary branches are formed when pseudopods 
guide the development of capillary sprout growth into the surrounding tissue. The 
capillary sprout hollows out to form a tube. The secretion of proteases induces the 
resolution of basal lamina, EC proliferation and migration towards chemotactic 
gradient. High oxygen levels with low concentration of hypoxia inducible factor 
(HIF) keeps the cells quiet. When the oxygen level is low, HIF-1α is expressed, 
upregulating many angiogenic genes. However, the strongest factor to be 
upregulated is VEGF, which guides the capillary sprouts (Pugh, Ratcliffe 2003). The 
rearrangement and remodeling of ECs to create new vessels is called intussusceptive 
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angiogenesis. This saves resources in the embryo, since EC proliferation is not 
needed for remodeling (Makanya, Hlushchuk & Djonov 2009, De Spiegelaere et al. 
2012).  
Physiological angiogenesis takes place in many conditions, e.g. in embryonic 
development, wound healing, ischemia and uterine function. Pathological 
angiogenesis is important in many diseases such as tumor growth, atherosclerosis 
and pathological neovascularization in the diabetic retina. In unwanted vascular 
growth, the basement membrane is degraded, ECs proliferate and migrate leading to 
the tube formation, remodeling and maturation of newly formed vessels (Djonov et 
al. 2000). 
Mature blood vessels have an EC layer lining the inside of the vessel, surrounded 
by supportive pericytes and SMCs. In addition to mechanical support, the 
perivascular cells regulate blood flow. The pericytes and SMCs also produce growth 
factors for ECs, like VEGF, FGF2 and Ang1. SMCs and pericytes stabilize mature 
vessels by preventing EC hyperproliferation (Bergers, Song 2005, Chan-Ling et al. 
2004, Hirschi, Rohovsky & D'Amore 1998). Long-term VEGF-A expression matures 
and stabilizes blood vessels (Djonov et al. 2000). VEGF-A also induces SMC and 
pericyte proliferation (Rutanen et al. 2004, Rissanen et al. 2005).  
The vasculature of specific organs, such as liver and spleen is highly permeable 
due to discontinuous ECs. The kidney and endocrine glands have fenestrated ECs. 
On the contrary, ECs in the brain and retinal capillaries have tight-junctions. Other 
tissues e.g. bone, skeletal muscle, myocardium and gonad capillaries, have 
continuous ECs. These findings have led to the concept of an organ-specific 
regulation of angiogenesis (Ioannidou et al. 2006, Stan, Kubitza & Palade 1999, 
Roberts, Palade 1995, LeCouter et al. 2001). 
2.1.4 Arteriogenesis 
Arteriogenesis is the growth and enlargement of arteries (collateral vessel formation) 
from pre-existing vessels (arterioles). Arteries enable a high-pressure transport of 
blood to capillaries, which is supported by SMCs and specialized matrix. The 
formation of collateral arteries to provide some blood flow to the ischemic tissue 
after the atherosclerotic occlusion of the main artery is of crucial importance as this 
may save the integrity of a lower limb or prevent myocardial infarction.  The driving 
force is blood pressure and increased shear stress against the endothelium, which 
causes the deformation of EC and SMC. In contrast, ischemia is not a direct force to 
drive collateral vessel formation as it occurs in non-ischemic area (Scholz, Schaper 
2005, Pipp et al. 2004). Nitric oxide synthase (NOS) and nitric oxide (NO) production 
activates VEGF expression from ECs and monocyte chemotactic protein (MCP) -1 
from SMCs. Macrophages have been postulated to play an important role in 
arteriogenesis by producing growth factors and matrix metalloproteinases (MMP). 
Macrophages and T-cells accumulate in the adventitia or become attached to 
endothelium. Basement membrane synthesis and turnover, cell-cell adhesion and 
contact inhibition, soluble factors and their receptors are all regulating arteriogenesis 
(van Royen et al. 2001, Kamihata et al. 2002, Heil et al. 2002, Buschmann et al. 2001).  
Arterial and venous ECs have specific molecular signatures that guide the cells to 
become differentiated (Swift, Weinstein 2009, Adams 2003). ECs become activated in 
response to shear stress with caveoli, integrins and tyrosine kinase receptors 
(VEGFR-1) acting as possible receptors. These activate multiple signaling pathways 
in the cells, and also shear stress response elements (SSRESs) are activated. 
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Circulating monocytes invade the vascular wall due to shear stress. Monocytes are 
transformed into macrophages and they start producing fibronectin, proteoglycans 
and proteases that remodel the ECM. Macrophages also produce vascular growth 
factors, mostly members of the FGF family. EC and SMC proliferation is stimulated 
by bFGF when it binds its receptors FGFR1-4 (Resnick et al. 2003). 
2.1.5 Lymphangiogenesis 
Lymphatic vessels are formed from differentiating lymphangioblasts or from pre-
existing veins. VEGF-C and –D together with VEGFR-3 are guiding the formation of 
vascular system (Kaipainen et al. 1995, Joukov et al. 1996, Achen et al. 1998, Makinen 
2001). VEGF-C and –D also bind to neuropilin (Nrp) -2, which is expressed in 
lymphatic capillaries supporting lymphatic development (Karkkainen et al. 2001, 
Yuan et al. 2002). In contrast to blood capillaries, the lymphatic capillaries consist of 
overlapping ECs, allowing macromolecules to penetrate the vessel wall and they 
also lack supporting pericytes. Lymphatic vessels are needed for fluid drainage from 
tissues, the immune system and absorption of lipids from the intestine. The main 
function is to collect excess fluid filtered from arterial capillaries into the interstitium 
where extra fluid is drained into lymphatic vessels through endothelial junctions. 
The fluid is returned to blood circulation at the left subclavian vein. Lymph nodes 
filter e.g. micro-organisms and cancer cells out of the lymphatic fluid. The lymphatic 
vessels in intestinal villi absorb lipids. Protective tissues (skin and mucous 
membranes) have a rich lymphatic network. They also have an important task in 
immune surveillance in importing antigens and antigen presenting cells into lymph 
nodes, and exporting immune effector cells and humoral responses into the blood 
circulation. Defects in the lymphatic system can cause lymph and fat accumulation, 
lymphedema and decreased immune responses (Lund, Swartz 2010, Jurisic, Detmar 
2009).  
2.2 VASCULAR GROWTH FACTORS 
Members of the VEGF-family and their receptors (VEGFR) are the main mediators in 
the formation of blood and lymphatic vessels in the developing embryo as well as in 
adults. Five members have been identified in the mammalian VEGF-family; VEGF-
A, -B, -C, -D and placental growth factor (PlGF) (Figure 2). 
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Figure 2. The VEGF family (VEGF-A, -B, -C, -D, -E, PlGF-1 and -2), their tyrosine kinase 
receptors (VEGFR-1, -2, -3) and neuropilins (Nrp-1 and -2) guiding vasculogenesis, 
angiogenesis and lymphangiogenesis (Ylä-Herttuala 2007). 
2.2.1 VEGFs 
VEGF-A is a major regulator in angiogenesis, in physiological and pathological 
conditions (Ferrara, Davis-Smyth 1997, Shibuya, Claesson-Welsh 2006). Its crucial 
role in angiogenic development has been shown with knockout (KO) mice, which 
die during embryonic development (Carmeliet 1996, Ferrara 1996). The mice have 
delayed EC differentiation, malformation of hematopoietic cells and disorganized 
blood vessels. VEGF-A signals via two tyrosine kinase receptors (VEGFR-1 and 
VEGFR-2). VEGF-A can induce vascular leakage, which relates strongly to 
inflammatory states and various pathological conditions. VEGF-A affects EC 
function by activating mitogen activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K) and other pathways (Ferrara, Gerber & 
LeCouter 2003). Multiple isoforms of VEGF-A are formed by alternative exon 
splicing, the main forms in humans are VEGF-A121, VEGF-A165, VEGF-A189 and 
VEGF-A206 named according to their amino acid length (Carmeliet 1996, Ferrara 
1996, Houck et al. 1991, Tischer et al. 1991). In mice the isoforms are VEGF-A120, 
VEGF-A164 and VEGF-A188 (Ferrara et al. 1992, Shima et al. 1996). They each have 
unique properties and bind differently to VEGFR-1, -2, -3, Nrp-1 and -2. The VEGF 
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activates its target cells to proliferate, migrate and alter gene expression (MMPs, 
cytokines) (Ribatti 2005, Ribatti 2008). VEGF-A165 is the major isoform. VEGF is the 
prime angiogenic molecule during development, adult physiology and pathology.  
In cancer therapy, inhibition of VEGF via the humanized monoclonal anti-VEGF 
antibody bevacizumab is used, which improves the patient’s survival (Braghiroli, 
Sabbaga & Hoff 2012, Rapisarda, Melillo 2012). VEGF via adenoviral overexpression 
has been a promising proangiogenic treatment for myocardial and lower limb 
ischemia (Hedman et al. 2003, Makinen et al. 2002). 
VEGF-B was discovered as a homolog to VEGF-A (Olofsson et al. 1996, 
Grimmond et al. 1996). VEGF-B has two spliced forms, VEGF-B167 and VEGF-B189, 
which bind differently to heparin adjusting their release and bioavailability. It forms 
heterodimers with VEGF-A (Olofsson et al. 1996, Olofsson 1996), changing receptor 
specificity and biological effects. VEGF-B is expressed in various tissues, mostly in 
heart and skeletal muscles (Olofsson et al. 1996). It is a survival factor for vascular 
ECs, pericytes and SMCs (Li 2008, Zhang et al. 2009). VEGF-B binds specifically to 
VEGFR-1 stimulating urinary plasminogen activator and plasminogen activator 
inhibitor-1 (PAI-1) expression and activation in ECs (Olofsson et al. 1998). It also 
binds to Nrp-1 (Makinen 1999). VEGF-B KO mice are viable but they have a smaller 
heart and coronary vasculature is impaired. In addition, recovery from induced 
myocardial ischemia is impaired (Bellomo 2000, Lahteenvuo 2009). VEGF-B 
deficiency restores insulin sensitivity and glucose tolerance in diabetic mice, 
evidence for a therapeutic function for VEGF-B antagonists (Hagberg et al. 2012).  
VEGF-C is closely related to VEGF-D with the N- and C-terminal extensions and 
they are proteolytically spliced into a mature form (Joukov et al. 1996, Kukk et al. 
1996). VEGF-C activates VEGFR-3; it has mainly a lymphangiogenic role, but it also 
possesses some angiogenic properties via VEGFR-2 and it also binds Nrp2 (Lohela et 
al. 2003). KO mice die at E15.5 due to the absence of lymphatic vasculature, which 
leads to fluid accumulation in tissues (Karkkainen et al. 2004). This indicates an 
important role for VEGF-C in embryonic lymphangiogenesis. The lymphatic ECs 
differentiate but they do not migrate and form the primary lymphatic sacks. A 
homozygous deletion leads to severe defects in lymphatic vessels. This shows the 
role of VEGF-C as a chemotactic and survival factor in lymphangiogenesis 
(Karkkainen et al. 2004). Overexpression of VEGF-C leads to hyperplastic lymphatic 
vessels (Jeltsch et al. 1997). Inhibition of VEGF-C signal transduction has been 
effective in preventing lymphatic metastasis of cancer. The stimulation of this 
pathway can be used in treating lymphedema (Tammela et al. 2005). 
 Similarly to VEGF-B, PlGF binds to VEGFR-1 and enhances angiogenesis in 
pathological conditions. PlGF is not needed in embryonic development, since KO-
mice are healthy and appear normal (Carmeliet et al. 2001). It is also dispensable in 
exercise-induced angiogenesis in the heart and muscle (Gigante et al. 2004). This 
suggests that in healthy adults PlGF is not needed for vasculogenesis or maintenance 
of vessels. However, PlGF KO-mice show impaired angiogenesis and arteriogenesis 
in pathological conditions such as tumors and ischemia (Carmeliet et al. 2001, Pipp 
et al. 2003, Luttun et al. 2002, Rakic et al. 2003). PlGF amplifies VEGF-A mediated 
angiogenesis via fms-induced tyrosine kinase (Flt-1) and fetal liver kinase (Flk-1) 
(Carmeliet et al. 2001, Luttun et al. 2002). PlGF also induces collateral growth of 
blood vessels by recruiting monocytes and by stimulating EC and SMC growth 
(Pipp et al. 2003, Luttun et al. 2002). PlGF also regulates the interaction between 
VEGF receptor tyrosine kinases (RTK) amplifying the effects of other VEGF-
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receptors (Autiero et al. 2003). PlGF has a potential therapeutic use in occlusive 
atherosclerotic disease. Adenovirus-mediated PlGF transfer in tumor xenografts 
resulted in growth of vessel lumen, increased inflammatory infiltration and vessel 
maturation (Tarallo et al. 2010). 
VEGF-D (also called c-fos induced growth factor, FIGF) was found by Achen et al. 
in 1998 (Achen et al. 1998). It is distinguishable from other VEGFs since the VEGF-D 
has N- and C-terminal extensions, similar to VEGF-C. In addition, it has a central 
VEGF-homology domain (VHD) and receptor binding domains. In mouse embryo, 
VEGF-D is expressed widely, but in adults it is abundantly expressed in heart, 
skeletal muscle, lung, small intestine and colon (Achen et al. 1998, Baldwin et al. 
2001, Avantaggiato et al. 1998). VEGF-D is secreted from cells as a full-length 
homodimer. Proprotein convertases cleave proproteins from both ends of the VHD 
to form a mature VEGF-D (McColl et al. 2007). The unprocessed VEGF-D binds 
mainly to VEGFR-3, whereas the mature protein can bind to VEGFR-2 as well. The 
mature hVEGF-D binds to VEGFR-2 with 290-fold affinity compared to unprocessed 
VEGF-D and with 40-fold affinity to VEGFR-3 (Stacker et al. 1999). By binding and 
activating these receptors, the VEGF-D mediates lymphangiogenic and angiogenic 
effects, respectively. Mouse VEGF-D binds only VEGFR-3 (Baldwin 2001). VEGF-D 
possesses distinctive functions in different species. The deletion of VEGF-D does not 
affect lymphatic development (Koch et al. 2009). However, in VEGF-C null mice, the 
lymphatic vessel sprouting is rescued by exogenous VEGF-D (Karkkainen et al. 2004, 
Baldwin et al. 2005). VEGF-D can promote metastasis of tumors via the 
prostaglandin system (Karnezis et al. 2012). Adenoviral VEGF-D overexpression 
induces efficient angiogenesis in the rabbit hindlimbs and pig myocardium (Rutanen 
et al. 2004, Rissanen et al. 2003b), showing potential for the use of VEGF-D in 
ischemic therapy. VEGF-D is also overexpressed in atherosclerotic plaques and has 
been shown to reduce neointimal growth after arterial injury (Rutanen et al. 2003, 
Rutanen et al. 2005).  
2.2.2 VEGF receptors 
Originally VEGF binding sites were found on the vascular EC surface but later they 
were found on monocytes and macrophages. Three main receptors are known that 
mediate the functions of VEGFs (Figure 2). Each receptor has seven extracellular 
immunoglobulin (Ig) like domains, one transmembrane domain and a cytosolic 
tyrosine kinase area with kinase insert domain (Shibuya et al. 1990, Takahashi, 
Shibuya 2005, Terman et al. 1991). VEGFs also interact with Nrp co-receptors. VEGF-
binding causes receptor dimerisation and autophosphorylation leading to 
intracellular signaling cascades (Figure 2). 
VEGFR-1 (Flt-1) was the first RTK that was found to bind VEGF. It binds also 
PlGF and VEGF-B (Shibuya 2006). In addition to ECs, VEGFR-1 is expressed in many 
cell types including monocytes, macrophages, vascular SMCs and hematopoietic 
stem cells, also in different tumor cells (Barleon et al. 1996, Zachary, Gliki 2001, 
Ishida et al. 2001, Fan et al. 2005). VEGFR-1 inhibits angiogenesis not only in early 
development but also in adults and it also signals for EC progenitor recruitment 
(Lyden et al. 2001), EC (Adini et al. 2002) and hematopoietic stem cell survival 
(Gerber et al. 2002), vascular permeability (Takahashi et al. 2004), monocyte 
migration (Barleon et al. 1996) and growth factor release (LeCouter 2003). KO mice 
die at E8.5-9.5 due to excess ECs, disorganized vasculature and obstruction of 
vascular lumen, pointing to a role in negative regulation of angiogenesis (Gille 2001, 
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Fong et al. 1995, Fong et al. 1999). Half of the embryos lacking the transmembrane- 
and tyrosine kinase domains die due to vascular malformations, suggesting an 
important role for VEGFR-1 localization in the membrane (Hiratsuka et al. 2005) 
Decreased VEGFR-1 expression is related to the formation of hemangiomas (Jinnin et 
al. 2008). VEGFR-1 is involved in tumor growth and metastasis. The stimulation of 
VEGFR-1 induces tumor angiogenesis indirectly via monocyte and macrophage 
activation. These cells migrate into inflammatory lesions and tumors, producing 
VEGF-A, VEGF-C and cytokines leading to angiogenesis and lymphangiogenesis 
(Lin et al. 2006, Murakami et al. 2008).  
VEGFR-2 (KDR, kinase insert domain containing receptor, Flk-1) is an endothelial 
RTK that is expressed on ECs and circulating bone marrow derived (BMD) 
endothelial progenitor cells (Kerbel 2008). It is a crucial player not only in embryonic 
vascular development, but also in pathologic angiogenesis in tumors. KO mice die 
between E8.5-9.5 due to impaired hematopoietic and ECs and the lack of a 
vasculature (Shalaby 1995). VEGFR-2 is the main activator of Raf/Mek/Erk 
(Takahashi et al. 1992, Takahashi, Ueno & Shibuya 1999) and PI3K- protein kinase B 
(Akt) pathways, causing EC growth, proliferation, migration, survival and adhesion 
(Ferrara, Gerber & LeCouter 2003, Kerbel 2008). VEGFR-2 is also a very important 
regulator of vascular permeability (Shibuya, Claesson-Welsh 2006). Anti-VEGFR-2 
antibody has been shown to inhibit primary and metastatic tumor growth in mice, 
highlighting the major role of VEGFR-2 in tumor angiogenesis (Hicklin, Ellis 2005). 
VEGFR-3 (or Flt-4) is similar to VEGFR-1 and -2. It binds the lymphangiogenic 
VEGF-C and VEGF-D as well as their processed forms and thus is important in 
vascular development, since KO’s are lethal after E9.5 due to reduced and 
disorganized EC and remodeling of blood vessels (Dumont et al. 1998). VEGFR-3 is 
expressed at embryonic primary plexus (Kukk et al. 1996) and later in the lymphatic 
vessels and endothelium (Kaipainen et al. 1995, Dumont et al. 1998, Pajusola et al. 
1992). VEGFR-3 is intensely expressed in heart, kidney and lungs (Kukk et al. 1996) 
and in vascular ECs during active angiogenesis (Tammela et al. 2008). Overall the 
expression of VEGFRs is very dynamic. Soluble VEGFR-3 expression leads to the 
regression of new lymphatic capillaries (Makinen 2001, Karpanen 2006). However, 
VEGFR-3 antibodies or the VEGFC/D trap affect only new lymphatic vessels, 
indicating that mature lymphatic vessels are not dependent on VEGFR-3 signalling 
(Karpanen 2006, Pytowski 2005). VEGFR-3 can also enhance the effects of VEGFR-2 
or sustain angiogenesis when VEGFR-2 is inhibited (Tammela et al. 2008). 
Nrp-1 and -2 are glycoproteins acting as co-receptors for VEGF. Nrp-1 forms a 
complex with VEGFR-2, enhancing the binding affinity of VEGF-A164 in mouse 
(Becker et al. 2005, Xu et al. 2011). Nrp-1 is expressed in arterial cells and takes part 
in vascular development and angiogenesis (Herzog et al. 2001, Lee et al. 2002) as 
well as neuronal development (Kawasaki et al. 1999). Nrp-1 null mice have defects in 
embryonic vascular remodeling and large vessel development (Kawasaki et al. 1999), 
whereas Nrp2 is mostly expressed in venous cells. It is needed for small lymphatic 
vessel and capillary formation (Yuan et al. 2002, Herzog et al. 2001). VEGF-B 
stimulates myocardial angiogenesis and arteriogenesis via Nrp-1 (Lahteenvuo 2009). 
Blocking of Nrp-1 enhances the effect of bevacizumab in tumor models by reducing 
the affinity of VEGF for ECs (Pan et al. 2007). The blockade of Nrp-2 inhibits tumoral 
metastases (Caunt et al. 2008). 
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2.2.3 Other vascular growth factors 
PDGF-A, -B, -C, and –D are secreted by ECs and SMCs and they recruit mural cells 
(Lindahl et al. 1997a, Lindahl et al. 1997b). PDGFs are required for co-migration and 
proliferation of supporting cells of the vasculature (Hellstrom et al. 1999). PDGF-B 
takes part in maturation, remodeling and stabilization of blood vasculature (Jain 
2003). PDGF-BB secreted by ECs recruit pericytes and this stabilizes blood vessels. 
PDGF-BB binds to heparin sulphate proteoglycans in the ECM (Lindblom et al. 
2003). PDGF-B KO-mice are embryonic lethal due to microvascular aneurysms and 
the lack of pericytes (Hellstrom et al. 2001). Recombinant PDGF-C mobilizes 
endothelial progenitor cells during ischemia and improves revascularization in 
ischemic limbs and heart. PDGF-C also induces bone marrow cell differentiation into 
ECs and SMCs. (Li et al. 2005) However, overexpression of PDGF-C and –D leads to 
cardiac fibrosis and heart failure (Korpisalo et al. 2008a).   
HIF-1α and HIF-2α are transcription factors regulated by hypoxic conditions. 
They adapt tissue responses to low oxygen tension (Semenza 1999) regulating the 
expression of genes related to angiogenesis, erythropoiesis, glycolysis and other 
pathways (Gopfert et al. 1996, Ebert et al. 1996, Takagi, King & Aiello 1998, Forsythe 
et al. 1996). Hif-1a can activate the migration of endothelial precursors via VEGF 
induction (Semenza 1999). 
The FGF-family consists of 23 members that bind to four tyrosine kinase 
receptors, which are involved in mediating multiple functions. FGF-1 and -2 are 
intracellular proteins that function during embryonic vascular formation, however 
not as a critical factor (Miller et al. 2000). FGF-4 and -5 are secreted proteins which 
partly function by inducing the VEGF expression in vascular ECs (Rissanen et al. 
2003a, Giordano et al. 1996). FGFs are also involved in physiological angiogenesis as 
well as in tumors (Gille 2001). Antibodies binding FGFs have prevented 
glioblastoma growth in mice (Ferrara et al. 1992, Takahashi et al. 1991). FGFR-1 
activation stimulates EC proliferation, migration and tubule formation (Basilico, 
Moscatelli 1992). However, FGFs are not involved in neovessel development (Hatva 
et al. 1995). 
Ang1-4 are a family of growth factors that are ligands for Tie1 and -2 receptors 
(Valenzuela et al. 1999, Davis et al. 1996, Maisonpierre et al. 1997). However, the role 
of angiopoietins in angiogenesis is somewhat controversial. Under certain 
conditions, Ang1 functions as a proangiogenic factor by stabilizing blood vessels and 
protecting them from leakage. Ang1 blocks the redistribution of vascular endothelial 
cadherin by inhibiting Sarcoma (Src), a tyrosine kinase proto oncogene (Gavard, 
Patel & Gutkind 2008). Ang2 has a diverse role depending on the environment and 
the presence of other growth factors, promoting or regressing vessel growth 
(Maisonpierre et al. 1997, Holash, Wiegand & Yancopoulos 1999). Ang3 and Ang4 
can also act context dependently, inhibiting or inducing Tie2 phosphorylation. 
However, their biological role is unclear (Valenzuela et al. 1999, Lee et al. 2004). 
2.3 DISEASES ASSOCIATED WITH VEGFS 
Angiogenesis is triggered by hypoxic stimulus in physiological as well as 
pathological conditions such as ischemia or tumors (Moreno, Purushothaman & 
Purushothaman 2012). VEGFs are the best characterized angiogenic molecules and 
used in clinical therapy (Table 1) (Ylä-Herttuala 2007). 
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Table 1. VEGF associated conditions  
 
Ligand Receptor Biological function Clinical 
manifestation 
VEGF-A       
VEGF-A165 
VEGF-A145 
VEGFR-1, VEGF-R2 
Nrp-1, Nrp-2 
Nrp-2 
Vasculogenesis, angiogenesis, 
vascular homeostasis and 
permeability, recruitment of BMD 
cells 
↑Diabetic retinopathy, 
↓PAD, ↓CAD 
PlGF 
PlGF152 
VEGFR-1 
Nrp-1, Nrp-2 
Angiogenesis, monocyte migration, 
recruitment of BMD cells, VEGF-A 
upregulation 
↓Pre-eclampsia 
↑ Myeloid leukemia 
VEGF-B VEGF-R1, Nrp-1 Angiogenesis, recruitment of BMD 
cells 
↑Type 2 diabetes, 
↓Hypertrophic 
cardiomyopathy 
VEGF-C VEGF-R2, VEGF-R3,   
Nrp-2 
Lymphatic development, 
lymphangiogenesis, angiogenesis 
↑Lymphatic 
metastasis, ↓CAD 
VEGF-D VEGF-R2, VEGF-R3 Angiogenesis, lymphangiogenesis ↑Tumors, ↑Lymphatic 
metastases 
BMD = Bone marrow derived, PAD = Peripheral arterial disease, CAD = Coronary arterial 
disease, ↑↓ High/low expression associating with the disease 
2.3.1 Atherosclerosis 
Atherosclerosis is an inflammatory state of the arterial wall. Chronic inflammation 
leads to complex lesions that grow towards the arterial lumen and obstruct the blood 
flow (Libby 2012). The intima grows thicker, thus decreasing the oxygen supply and 
the inflammatory state consumes more oxygen. This leads to hypoxia that triggers 
transcriptional processes mediated mainly by HIF-1a, finally leading to upregulation 
of angiogenic factors (Sluimer, Daemen 2009). The lesions may rupture and form a 
thrombus, which blocks the circulation completely, causing myocardial infarction, 
stroke or acute lower limb ischemia. The hypoxic areas in the lesion are 
characterized by macrophage infiltration and thrombus formation (Sluimer et al. 
2008). 
2.3.2 Cancer 
Angiogenesis is a crucial factor in tumor growth, progression and metastasis (Kerbel 
2008). When a tumor grows large enough, the central cells do not have adequate 
amounts of nutrients and oxygen inducing hypoxia in the tumor. This stimulates the 
production of HIFs, VEGFs, PDGF and NOS, which are upregulated in tumors 
growing and remodeling the blood and lymphatic vasculature (North, Moenner & 
Bikfalvi 2005). Tumor vasculature and structure are distinct from normal vessels; 
leaky, twisted and immature (Hiratsuka 2011). VEGF-A is over-expressed in many 
types of tumors; colorectal cancer, non-small cell lung cancer and renal cell cancer 
(Ferrara 2005). VEGF-A may also inhibit anti-tumoral immune response. Since it can 
stimulate the formation of tumoral blood vessels, VEGF-A promotes tumor growth. 
VEGF-A also promotes tumor invasiveness by upregulating MMPs (Munaut et al. 
2003) In addition, VEGF-B expression is increased in many tumor types (Hanrahan 
et al. 2003, Gunningham et al. 2001) and the extent of the upregularion correlates 
with disease stage, vascular invasion, microvascular density and patient survival in 
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different carcinomas (Eggert et al. 2000, Kanda et al. 2008, Mylona et al. 2007, 
Shintani et al. 2004). VEGF-C and -D induce lymphatic vessel growth and promote 
tumoral metastasis to lymph nodes (Karnezis et al. 2012, Stacker et al. 2001). VEGF-C 
also promotes intralymphatic tumor growth (Karpanen 2001), whereas the 
downregulation of VEGF-C expression inhibits tumor growth and metastasis 
(Khromova et al. 2011). 
Anti-angiogenic factors could disable the oxygen and nutrient supply needed for 
tumor cells, inhibit sprouting and assembly of unstructured tumor vessels and 
diminish tumor growth and metastasis. This could restrain the growth of certain 
tumors. VEGF-A is expressed widely in malignant tumors and is considered to be 
the most important angiogenic factor. Antibodies targeting VEGF-A or its receptors 
prevent tumor growth in mice and tumor xenografts (Carmeliet, Jain 2011, Kim et al. 
2002, Inai et al. 2004, Zhu et al. 2009). On the contrary, some studies have shown 
conflicting results via induction of hypoxia and alternate angiogenic pathways. 
Some studies show that the reduction of tumor vasculature increases tumor 
metabolism and metastases (Paez-Ribes et al. 2009). Stabile vessels supported by 
pericytes are resistant to anti-VEGF-A therapy (Erber et al. 2004). Clinical trials have 
shown only a transient increase in survival of patients with solid tumors treated 
with antibodies, bevacizumab alone or as part of combination therapy (Sandler et al. 
2006, Miller et al. 2007, Presta et al. 1997, Hurwitz et al. 2004). The effect of 
antiangiogenesis is dependent on the drug dosage and timing of the treatment 
(Tugues et al. 2011). These findings indicate that the growth of tumors is a complex 
event with ECs, oxygen and nutrients playing a central role, but other regulatory 
factors are involved as well. 
2.3.3 Lymphatic disorders 
Abnormal lymphatic development or damage to the lymphatic vessels causes 
lymphedema, which is a progressive and non-curable disease. The excess interstitial 
fluid induces inflammatory reactions, causing fibrosis, accumulation of adipose 
tissue and impaired immune responses and wound healing (Rockson 2001, Warren 
et al. 2007). Lymphedemas are classified as primary (congenital) or secondary, and 
can be induced by surgery, trauma, radiotherapy or a parasitic infection. Primary 
lymphedemas are caused by genetic mutations in crucial lymphatic factors, such as 
VEGFR-3 (Evans et al. 1999, Connell et al. 2009) and forkhead box protein (FOX) C2 
(Fang et al. 2000, Mangion et al. 1999, Brice et al. 2002). In addition, other genes are 
involved and the outcome in patients is variable. Most lymphedemas worldwide are 
classified as secondary and are caused by several types of external factors. The most 
common type is lymphatic filariasis caused a parasitic infection in the lymphatic 
vessels. The inflammation promotes the production of VEGFs, which eventually 
leads to hyperplasia and obstruction of lymphatic vessels (Melrose 2002, Pfarr et al. 
2009). In the industrialized countries, cancer treatments are the major cause for 
secondary lymphedema. Tumors frequently form metastases into lymph nodes, 
which require surgical removal and radiotherapy. This operation may cause 
problems with the lymphatic flow (Warren et al. 2007). 
2.3.4 Disease models 
Different disease models have been created to study ischemic conditions and tumor 
angiogenesis and they have been proved to be good tools in clarifying the 
mechanisms of pathological angiogenesis and studying anti- and pro-angiogenic 
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treatments. In the hindlimb ischemia (HLI) model (Kholova et al. 2007) the femoral 
artery is usually ligated to induce ischemia in the skeletal muscles. This model 
makes it possible to study neovascularization and proangiogenic treatments. The 
method is relatively easy to perform in mice and is reproducible. After the ligation of 
the artery, new collateral vessels are formed and there is induction of sprouting 
angiogenesis (Korpisalo et al. 2008b, Koponen et al. 2007). This can be visualized 
with a variety of methods, including immunohistochemistry or different in vivo 
imaging methods. The mouse retinal vasculature is also a good model with which to 
study human retinopathy of prematurity or diabetic retinopathy, that are common 
complications of diabetes (Kinnunen, Yla-Herttuala 2012, Viita et al. 2009). 
2.4 GENERATION OF GENE MODIFIED ANIMALS 
2.4.1 Traditional ways of creating transgenic and knockout animals 
TG, KO and KD methods are now recognized as a valuable research tool in biology. 
Basically two different approaches can be used to acquire genetically modified 
animals, either increasing or decreasing gene expression. Genetic material can be 
delivered via ESCs or into different stage embryos. Plasmids and naked DNA 
(deoxyribonucleic acid) have been used in gene transfer, however, they proved to be 
inefficient in vivo. The material can be complementary DNA (cDNA) expressing a 
desired gene or alternatively, a small RNA that inhibits the expression of the target 
gene.  
In traditional DNA microinjection (MI), a gene construct is injected into the 
pronucleus of a fertilized oocyte. This was the first effective method devised in 
mammals (Gordon, Ruddle 1981). The introduced DNA can either cause 
overexpression of the desired genes or it can silence it. The DNA is introduced 
randomly into the host genome and the wanted product may not be expressed at all. 
The fertilized oocyte is transferred into a recipient pseudopregnant female. This 
method can be applied to a wide variety of species, such as rodents, pigs and avians 
(Gordon et al. 1980). 
In embryonic stem cell (ESC) -mediated gene transfer, the desired DNA sequence 
is inserted by homologous recombination into ESCs. These cells are incorporated 
into a blastocyst embryo, finally leading to the birth of a chimeric animal. This is a 
good method for achieving gene inactivation working especially well in mice 
(Gordon, Ruddle 1981). 
The techniques mentioned above are relatively inefficient, since the probability for 
obtaining live TG animals is very low. Viruses have been modified for use in gene 
delivery in an attempt to improve efficiency (Somia, Verma 2000). Retroviruses 
allow proviral integration into the genome of a host animal (Hofmann et al. 2003). 
This is an efficient method and requires less oocytes in comparison to most other 
methods.  
2.4.2 Transgenesis, knockout and knockdown methods based on lentiviral gene 
transfer 
Lentiviruses (LV) offer some advantages over retroviruses, such as a capacity to 
transduce quiescent cells. The LV can be injected into the pronucleus of an oocyte, or 
with a less invasive method into the perivitelline space (Huusko et al. 2008, Tiscornia 
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et al. 2004). The commonly used methods for creating TG, KD and KO animals are 
listed in Table 2. 
The LVs used in transgenesis are usually third-generation self-inactivating (SIN) 
vectors, to prevent viral replication (Miyoshi et al. 1998, Zufferey et al. 1998). The 
promoter is chosen according to the study needs; tissue specificity, strength or 
regulatability. In order to create TG mice, LV containing the desired gene is 
delivered into perivitelline space of a fertilized oocyte (Huusko et al. 2008). Several 
of these oocytes are transferred into the oviducts of recipient females. This MI 
method is demanding and the equipment is expensive. In comparison to other 
methods, the perivitelline injection (PI) -technique is gentle on the embryos and the 
integration happens at the one-cell stage, creating non-mosaic animals. However, a 
high viral titer is needed for the PI-method. The founder mice are analyzed for 
transgene positivity.  
The gene silencing technique involves RNAi, with RNA polymerase III (polIII) 
promoters human U6 small nuclear promoter (U6) and human H1 (H1) most often 
being used to express the shRNA. They are very strong ubiquitous promoters and 
easily fit into expression cassettes and they have been shown to silence gene 
expression over the long-term in mice (Makinen et al. 2006, Raoul et al. 2005). The 
first described LV-KD mice was an H1-driven silencing of green fluorescence protein 
(GFP) expression (Tiscornia et al. 2003). In addition, the U6 promoter has been 
effectively used to silence CD8 (cluster of differentiation 8) (Rubinson et al. 2003). 
The shRNA cassette can be inserted into the multiple cloning site (MCS), upstream 
of the marker gene, or the lentiviral 3’-LTR (long-terminal repeat). Nevertheless, the 
generation of KD mice with RNA polymerase III (polIII) promoters has proved to be 
challenging (Carmell et al. 2003, Xia et al. 2006) due to the strong and ubiquitous 
nature of the promoters. A strong expression of the shRNA may lead to micro RNA 
(miRNA)-pathway saturation and disturbance in endogenous miRNA function 
(Grimm et al. 2006). Furthermore,  non-specific silencing and inflammatory reactions 
may occur (Bridge et al. 2003). Regulatable polIII promoters have also been used in 
attempts to resolve the saturation problem. This has been done with Cre-loxP 
(bacteriophage P1 Cre recombinase and Lox sequence) systems (Ventura et al. 2004) 
and with a drug inducible mechanism (Szulc et al. 2006). Recently, polII promoters 
that mimic the endogenous miRNA structure have been used as a more natural 
silencing method. The shRNA is expressed as a long pre-miRNA (Zeng, Cai & 
Cullen 2005) allowing the use of more flexible, controllable and tissue-specific polII 
promoters (Lee et al. 2004). 
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Table 2. Commonly used methods for creating TG, KD and KO animals. 
 
Method Technique Effect Pros Cons 
ESC Transfection, 
Electroporation, viral 
transduction, 
Homologous 
recombination 
TG, KD, 
KO 
Selection in cells, 
locus specific 
Chimeras, restricted species, 
challenging cell culturing, 
random integration 
PIE Microinjection, 
cytoplasmic injection 
TG,KD Gentle for embryos, 
non-chimerism 
Heterogenic founders, 
Damage to embryo 
PI Microinjection TG,KD Gentle for embryos, 
non-chimerism 
Technically demanding, 
expensive equipment, high 
viral titer 
ZP Viral medium 
incubation 
KD Technically easy Toxic to embryos, mosaic 
ESC, Embryonic stem cells (Hogan et al. 1994, Pfeifer et al. 2002); PIE, Preimplantation 
embryos (Gordon et al. 1980, Haraguchi et al. 2004); PI, Zygote perivitelline injection 
(Huusko et al. 2008, Tiscornia et al. 2003); ZP, Zona-pellucida denuded embryos (Ikawa 
et al. 2003). 
2.4.3 Gene silencing 
miRNA are noncoding RNA molecules found in mammals and many other 
eukaryotes. The precursor miRNAs have a hairpin structure that is processed into a 
mature form by a Dicer enzyme into 21-23 nucleotide double-stranded (ds) RNA 
molecules, small interfering RNA (siRNA). In this way one can regulate gene 
expression specifically through RNAi and related pathways (Hannon 2002, 
Pasquinelli, Ruvkun 2002, Meister, Tuschl 2004, Hannon, Rossi 2004). The siRNA 
interacts with RNA-induced silencing complex (RISC) and the sense strand is 
cleaved by Argonaute 2 (Ago2) (Matranga et al. 2005). The antisense strand guides 
RISC by sequence homology to the target messenger RNA (mRNA), which is 
degraded by Ago2, resulting in specific gene silencing (Geiss et al. 2001). A synthetic 
dsRNA similar to the processed siRNA can achieve a specific gene silencing in 
mammalian cells without inflammatory response (Elbashir et al. 2001). This finding 
has led to the widespread use of RNAi in genetic research.  
RNAi is an effective tool for functional gene studies compared to the genetic KO 
method. RNAi is a conserved mechanism that is very sequence specific (Hannon, 
Rossi 2004). Synthetic siRNA or small hairpin (sh) RNA introduced by a vector can 
be used to induce the RNAi mechanism. In the shRNA method, an oligonucleotide 
containing the wanted siRNA sequence following a 9 nucleotide hairpin loop and a 
complement siRNA sequence is cloned into the vector of choice. When introduced 
into the cells, the shRNA is expressed and processed via the intracellular processing 
machinery into siRNA. Synthetic siRNA is quickly diluted and degraded, but the 
shRNA are produced in the cells and the silencing effect is long-lasting. Different 
viral vectors have been used to deliver shRNA to cells, and used for a variety of 
purposes. LVs have been preferred due to their integrative property which achieves 
long-term expression of shRNA and gene silencing. Viral vectors are effective in 
gene delivery, but they also have their disadvantages (Van den Haute et al. 2003). 
There has been some variance in the production of shRNA TG animal models due to 
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a variety of reasons; promoters, vectors, technical performance etc. shRNAs can 
cause either stable or transient gene silencing. 
2.4.4 Viral vectors 
Viruses have a variety of properties that can be modified to accommodate the 
specific needs for gene transfer and therapeutic use (Table 3). If one wishes to use a 
virus as a vector, part of the viral genome is removed, such as structural proteins 
and enzymes. This strips the virus of its reproductive and infective capabilities. The 
necessary genetic elements are brought in the viral production step via helper 
constructs or packaging cell lines, which reduces the risk of generating replication 
competent viral vectors. The required elements for the desired gene expression are 
also added.  
 
Table 3. Commonly used vectors for gene transfer 
 
Vector Pros Cons 
Lentivirus Long-term expression 
Transduction of dividing and quiescent cells 
Integrating 
Low immune response 
Difficult to produce high-
titer vectors 
Random integration 
Adenovirus High capacity            
High-titer production  
Efficient transduction, also quiescent cells      
Wide tropism 
Transient expression  
Immune and inflammatory 
responses 
Adeno-associated 
virus 
Long-term expression  
Integrating 
Serotype specific tropism  
Transduction of dividing and quiescent cells 
Low immune response 
Low capacity                    
Low-titer production 
Random integration 
Retrovirus Easy production              
Long-term expression   
Integrating 
Low immune response 
Transduces only dividing 
cells                             
Random integration  
Low efficiency 
Non-viral vectors Easy production          
Safety 
Non-pathogenic 
Inefficient (cell entry, 
instability, degradation)         
Transient expression 
Baculovirus Transduction of dividing and quiescent cells 
Large capacity 
Non-pathogenic 
No replication in mammalian cells  
Transient expression 
Immune and inflammatory 
responses 
Modified from (Rissanen, Yla-Herttuala 2007). 
 
LVs belong to the retroviruses, with a diploid RNA genome inside the viral 
capsid. They bind to receptors on the cell surface and then the viral capsid with the 
genome fuses to the cell membrane gaining entry into the cell. Viral RNA is 
transcribed into ds provirus DNA with a reverse transcriptase enzyme. Provirus-
DNA integrates into the host genome and replicates with the cell’s DNA 
(Panganiban, Fiore 1988, Varmus, Swanstrom 1985). The incubation time of LVs is 
long (lenti = slow). The infection is long-term and targets several organs. There are 
five different serotype groups; bovine immunodeficiency virus (BIV), horse, feline 
(FIV), sheep and primate (HIV 1-3, SRV-1, SIV). Once an individual is infected, the 
virus is present permanently. LVs integrate into the genome and are able to avoid 
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immune defense, and this makes possible their long-lasting effects (Park et al. 2000, 
Naldini et al. 1996a). 
Vectors have been developed from all types of LVs, but HIV-1 derived have been 
the most extensively studied. Almost all of the viral sequences have been removed, 
leaving only essential parts. The transgene is cloned between the LTR-regions to 
allow it to integrate into the target cell genome. A Psi-sequence, which is 
immediately adjacent to the LTR, is needed for RNA packaging into viral particles. 
The viral envelope proteins (Env) are produced in packaging cells. LV vectors are 
produced with the help of a transfer plasmid including parts of the HIV provirus 
and three helper plasmids having Rev (regulating viral RNA export to nucleus), 
packaging construct and Env. These plasmids are transfected into packaging cells to 
produce the HIV vectors (Dull et al. 1998). 
LVs transduce efficiently a variety of cells, including non-dividing cells (Naldini 
et al. 1996b, Trono 2000). They can be used in highly differentiated cells such as 
neurons and cardiomyocytes (Naldini et al. 1996b, Naldini 1998, Sakoda et al. 1999). 
Furthermore, they can even infect cells of the immune system. LVs are able to 
mutate rapidly if subjected to a host immune response. Integrating vectors may have 
harmful side-effects due to random integration (Springer et al. 1998). Regulated 
vector systems would be needed to maintain keep the transgene expression at an 
optimal level.  
2.5 PHENOTYPE ANALYSIS OF GENE MODIFIED ANIMALS 
Genetically modified animals are good models for studying human physiology and 
diseases. One can evaluate the function and the effect of a single gene in a living 
organism. However, one has to be aware of the effects of genetic background and 
variability in transgene integration. A transgene does not necessarily model a single 
disease, rather the effect is more widespread. Changes may affect metabolic 
pathways with no clear visible signs. In addition, there may be unexpected changes 
caused by gene modification that may be difficult to discern. Furthermore, most of 
the acquired diseases such as cardiovascular diseases or cancer are due to abnormal 
function of many different genes and environmental factors. These issues pose 
additional challenges to the research. 
Gene modification is basically the addition, deletion or alteration of DNA, leading 
to a change in gene expression. The selection of the background strain is essential, 
since this will affect the outcome of the transgene effects and also of possible disease 
phenotypes (Linder 2001). Most inbred strains have been well characterized and 
changes in the phenotype are relatively easy to detect. For many genes a regulated 
system should be used in order to avoid lethality due to lack of or constant 
overexpression of an essential gene. These can be achieved with Cre-loxP or 
tetracycline-based transgene constructs. This allows the gene expression to be 
controlled in a time-dependent manner (Dull et al. 1998, Marumoto et al. 2009). The 
transgene may cause problems in viability or reproduction in a homozygous animal. 
Alternatively, the wanted phenotype may be visible only in the homozygous animal. 
In such cases, a breeding strategy should be considered in order to maintain the 
wanted phenotype (Murray, Parker 2005). 
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3 Aims of the study 
The aim of this thesis was to assess the perivitelline injection (PI) as a method for 
creating TG mice. A secondary aim was to study the biological function of VEGF-D 
using TG and KO mice. 
 
The specific aims of this thesis were: 
 
I To study the efficiency of the PI technique and lentiviral transgenesis. It was also 
intended to assess the long-term effects of human VEGF-D expressed under a 
ubiquitous phosphoglycerate kinase (PGK) promoter. 
 
II To study the effects of hVEGF-D overexpression targeted to endothelium by a 
mouse Tie1 promoter and to compare the effects of targeted VEGF-D expression 
to ubiquitous VEGF-D expression. 
 
III To clarify the role and relevance of VEGF-D in vivo, by creating and characterizing 
mice with lentiviral RNAi-mediated gene silencing of VEGF-D. 
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4 Materials and methods  
Materials and methods are briefly listed in the Tables 4-8 and Figure 3. More details 
are described in the original publications (I, II) and a manuscript (III). 
4.1 VECTORS 
The mature human VEGF-D (hVEGF-DΔNΔC) (Achen et al. 1998) was cloned under 
the ubiquitous human PGK promoter (Study 1) and an endothelial mouse Tie1 
promoter (Study 2) with a lentiviral backbone. shRNA for mouse VEGF-D was 
cloned under the hU6 promoter for use in study III (Figure 3). The constructs were 
verified by sequencing analysis. The 293T cells were transfected with cloned 
plasmids to produce the viruses (Kaikkonen et al. 2009). Viruses were titered by 
lentiviral capsid protein p24 by enzyme-linked immunoassay (ELISA) and converted 
into transforming units (TU). 
 
 
 
 
 
Figure 3. Lentiviral vectors used in PI. The vector backbone contains CMV, 
cytomegalovirus promoter; U5, 5’ LTR; Ψ, packaging signal; RRE, rev-responsive 
element; cPPT, central polypurine tract and dU3, deletion in the U3. The TG cassettes 
contain the human phosphoglycerate kinase (hPGK) promoter (Study I), truncated 
human VEGF-D (hVEGFDdNdC), woodchuck hepatitis virus pre response element (WPRE), 
endothelial mouse Tie1 (mTie1) promoter (Study II), human U6 (hU6) promoter (Study 
III), shRNA against mouse VEGF-D (shVEGFD) and truncated human nerve growth factor 
receptor (dNGFR) as a marker gene.  
Titers of the concentrated LVs are shown in Table 4. The functionality of the viruses 
was confirmed after transduction and PIs were performed.  
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Table 4. Lentivirus constructs and their viral titers used in the studies 
 
Construct Titer 109 TU/ml 
PGK-hVEGFD 1.90 
Tie1-hVEGFD 1.20 
hU6-shVEGFD 1.80 
4.2 GENERATION OF TRANSGENIC AND KNOCKDOWN MICE 
Female CD2F1 mice (9-12g, 3-5 weeks) were superovulated by administrating 
intraperitoneally PMSG (5 IU) hormone and 48h later hCG (5 IU) timed with the 
light cycle. The females were mated with a breeder male to fertilize the eggs. Oocytes 
were collected from the donor mice. The virus (50-200pL) was injected into the 
oocyte perivitelline space. The oocytes were grown to the 2-cell stage and transferred 
to a pseudopregnant CD2F1 mice. The LV-PI method was gentle on the embryo, and 
thus a high amount of embryos survived to a 2-cell-stage. Although the number of 
births was very low compared to other methods, it did achieve a high percentage of 
TG-positive offspring. The efficiency of the LV PI-technique is presented in Table 5. 
Pups were weaned at 3 weeks and genotyped by polymerase chain reaction (PCR) 
analysis. The primers used are listed in Table 6.  
 
 
Table 5. Effect of LV PI-transgenesis compared to traditional methods 
 
Method Injected 
embryos 
Two-cell stage 
embryos 
Transferred 
embryos 
Births (% from 
transferred 
embryos) 
Transgenic pups 
(% from Births) 
PIa 635 601 507 19 (4%) 15 (79%) 
PIb 622 509 463 160 (35%) 115 (72%) 
ZP - - 330 71 (22%) 50 (70%) 
ZCI 132 95 95 32 (34%) 24 (75%) 
ESC 214 76 56 5 (9%) 1 (20%) 
ZPI 257 175 175 20 (11%) 8 (40%) 
PIa (mice used in studies I, II and III), Perivitelline injection into zygote (Huusko et al. 
2008); PIb (Lois et al. 2002, Punzon et al. 2004, Yang et al. 2007); ZP, Zona pellucida-
denuded two-cell stage embryos (Ikawa et al. 2003); ZCI, Zygote cytoplasmic injection 
(Yang et al. 2007); ESC, Embryonic stem cells (Hogan et al. 1994); ZPI, Zygote 
pronuclear injection (Gordon, Ruddle 1981). 
 
Table 6. DNA oligonucleotides used in genotyping 
 
Description Sequence Used in 
hVEGF-D Fw TTGCCAGCTCTACCACCAG I, II 
hVEGF-D Rev TTCATTGCAACAGCCACCAC I, II 
hU6 Fw GAGGGCCTATTTCCCATGATT III 
WPRE Rev TCAGCAAACACAGTGCACACC III 
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4.3 TRANSGENE EXPRESSION 
Transgene copy numbers were analyzed by Southern blot method from genomic 
DNA, which was extracted as described (Invitrogen) and digested with AflII (New 
England Biolabs, Inc) restriction endonuclease. Electrophoresis was used to separate 
the digested DNA, and it was transferred to a nitrocellulose membrane. Membrane 
was hybridized with 32P-CTP (cytidine triphosphate) labeled WPRE probe and 
developed on a film. Quantitative PCR (qPCR) with lentiviral titering kit (SystemBio, 
LV960B-1) was also used to determine the copy number in study III. 
Transgene expression was analyzed from various tissues of the mice. Total RNA 
was isolated and reverse transcribed into cDNA. qPCR was used for mRNA 
expression analysis with Assay-on-demand gene expression products (Applied 
Biosystems) (Table 7). Expression levels were normalized against mouse β-actin 
control kit (Applied Biosystems). 
 
Table 7. Gene expression assays 
 
Gene Taqman® gene expression assay 
human VEGF-D ID: Hs01128659_m1 
mouse VEGF-D ID: Mm00438963_m1 
4.4 ISCHEMIA OPERATIONS 
Mice were anesthetized with a Rompun-Ketalar mixture (10 mg/kg xylazine 
[Rompun], 80 mg/kg ketamine) and the superficial femoral artery was ligated 
(Kholova et al. 2007). The animals were sacrificed at 1, 2 and 3 week timepoints and 
their organs perfused with phosphate buffered saline (PBS) so that the relevant 
tissues could be collected for further analysis. The histological specimens were fixed 
in paraformaldehyde (PFA), processed and embedded in paraffin. Tissues were snap 
frozen in liquid nitrogen for DNA and RNA analyses. 
4.5 HISTOLOGICAL ANALYSES 
The major organs (heart, aorta, lungs, salivary glands, liver, spleen, pancreas, 
kidneys, testis/ovaries, small intestine, limb muscles, brain and skin) of genetically 
modified and control mice were sectioned (5 μm), stained with hematoxylin-eosin 
(HE) and analyzed for major phenotypic changes. A more detailed analysis was 
conducted by immunostaining with the antibodies listed in Table 8.  Avidin biotin 
complex (ABC) Vectastain Elite staining kit (Vector Laboratories, Burlingame, CA) 
and diaminobenzene (DAB) (Invitrogen Zymed, San Francisco, CA) were used for 
immunohistochemistry. Transgene negative littermates were used as controls in the 
pathological analysis. In the HLI studies, blood and lymphatic capillary density was 
determined (Kholova et al. 2007) and tissues of intact mice were used as controls. 
Histological sections were analyzed using the Olympus AX-70 light microscope 
(Olympus) with AnalySIS Software (Soft Imaging Systems). Malignant and benign 
tumors were evaluated together with an experienced pathologist (IK). 
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Table 8. Primary antibodies used in immunohistochemical stainings 
Antibody Specificity Dilution Supplier 
human VEGF-D (AF289) Vascular endothelial growth factor 
D * 
1:100 R&D Systems 
mouse VEGF-D (AF469) Vascular endothelial growth factor 
D 
1:50 R&D Systems 
CD31 (550274) Endothelium 1:50 BD Biosciences 
Pharmingen 
CD34 (HM1015) Endothelium 1:20 Hycult Biotechnology 
LYVE-1 (103-PA50AG) Lymphatic endothelium* 1:1000 ReliaTech 
VEGFR-2 (14-5821) Vascular endothelial growth factor 
receptor 2 
1:100 eBiosciences 
VEGFR-3 (552857) Vascular endothelial growth factor 
receptor 3 
1:50 BD Biosciences 
CK (SC 81714) Cytokeratin 1:50 Santa Cruz 
CK7 (SC 25721) Cytokeratin 7 * 1:50 Santa Cruz 
Ki-67 (ab6524) Proliferating cells 1:200 Abcam 
Myeloperoxidase (MAB 
3174) 
Myeloid cells* 1:30 R&D Systems 
Desmin (MA1-80003) Skeletal, cardiac and smooth 
muscle* 
1:200 Fisher Scientific 
CD3 (MAB 4841) T-lymphocytes** 1:50 R&D Systems 
CD45R/B220 (MAB 1217) B-lymphocytes 1:200 R&D Systems 
Vimentin (SC 7557) Vimentin/mesenchymal cells 1:50 Santa Cruz 
F4/80 (mcap497) Macrophages 1:25 Serotec 
* The use of antigen retrieving citrate buffer, ** Trypsin digestion, hVEGF-D antibody 
was anti-human, all others were anti-mouse 
4.6 PROTEIN EXPRESSION 
Tissue lysates and serum samples were collected at the time of sacrifice. Tissue 
samples were homogenized in T-PER buffer (Pierce Chemical, Rockford, IL). 
Quantikine immunoassays (human VEGF-D and mouse VEGF-A; R & D Systems, 
Minneapolis, MN) were used to analyze the hVEGF-D and mVEGF-A protein 
concentrations from individual mouse samples.  
4.7 CLINICAL CHEMISTRY  
Serum samples were analyzed using standard clinical chemistry methods 
(Department of Clinical Chemistry, Kuopio University Hospital and Movet OY, 
Kuopio) to detect markers for lipid metabolism, liver and kidney function, and tissue 
damage. 
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4.8 STATISTICAL ANALYSES 
Statistics were analyzed with Graph Pad Prism version 4.00 (Graph Pad Software, 
San Diego, CA). One-way analysis of variance (ANOVA) or unpaired, 2-tailed t-test 
was used with the analysis with 95% confidentiality for assessment of statistical 
significance (P < 0.05). The survival curve was analyzed with a nonparametric 
logrank test (P < 0.05). 
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5 Results 
5.1 GENERATION OF TG MICE AND VEGF-D EXPRESSION 
hVEGF-D overexpressing mice and mVEGF-D KD mice were produced through LV 
transgenesis. The lentiviral constructs used in PI and comparison are listed in Table 
9. In general, a high-percentage (91-100 %) of all injected embryos survived viral MI, 
but most of the transferred embryos died before birth. A significant proportion, 50-
100 % of the born founders were TG positive. Southern blot and qPCR analyses were 
used to determine the transgene copy numbers. In study I, the studied mice had 1-10 
copies of the transgene in the genome. In studies II and III, the copy number was 
between 1-5. The number of chromosomal integrations was analyzed in study I, and 
it was found that the provirus had mostly integrated into one chromosome. Two 
mice derived from the same founder had two integration sites. In all studies, the 
transgene was transmitted from one generation to the next. 
 
Table 9. Lentiviral PI 
 
Construct Injected 
embryos 
Two-cell 
stage 
embryos 
Transferred 
embryos 
Births Transgenic pups 
(% of births) 
PGK-GFP 98 95 68 6 5  (83.3) 
PGK-VEGF-D 145 132 114 4 4  (100) 
Tie1-GFP 240 228 192 3 2  (66.7) 
Tie1-VEGF-D 22 22 22 2 2  (100) 
hU6-shVEGF-D 130 124 111 4 2  (50) 
 
 
The TG mRNA expression levels varied between mice, as well as between tissues. 
However, certain tissues such as skeletal muscle and skin had the highest hVEGF-D 
expressions in all examined generations in studies I (Figure 4) and II with a similar 
trend being seen in the shVEGF-D mice. In study II, the TG was well expressed in 
the endothelium. The VEGF-D mRNA was detectable in all analyzed generations, 
however the expression levels did decline with advanced generations in study II 
(Figure 5). In study III the mVEGF-D expression levels were generally lower in KD-
mice in comparison to controls (Figure 6).  
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Figure 4. Relative hVEGF-D mRNA expressions from the TG-mice in study I revealing the 
general pattern of TG expression in the different tissues. The same pattern was also 
observed in studies II (hVEGF-D) and III (mVEGF-D). 
 
 
Figure 5. The hVEGF-D expression in the Tie1-hVEGFD TG mice. The average expression 
levels of tissues were grouped by generation. The levels were highest in founder mice 
and declined in later generations.  
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Figure 6. Relative expression levels of mVEGF-D mRNA by qPCR from KD mice (study 
III). The mVEGF-D expression levels of transgene negative littermate controls show a 
significantly higher expression compared to KD mice. *** p < 0.001, ** p < 0.005, * p 
< 0.05 
 
The level of protein expression of hVEGF-D was measured from tissue lysates 
(Study I). The expression levels between different generations were similar. No 
hVEGF-D was detected in TG-negative mouse samples. In serum samples, the 
hVEGF-D protein concentration varied between 20-700 pg/mL (study I) and 120-160 
pg/mL (study II). No mVEGF-D was detected with ELISA in shVEGF-D mice. 
Markers of lipid metabolism, liver and kidney function, and tissue damage were 
measured from serum of TG-positive and TG-negative mice (Table 10). Creatinine 
and glucose levels in study I were significantly lower than those assayed in studies II 
and III. The level of lactate dehydrogenase (LD) was lower in the TG positive mice in 
comparison to controls in all studies.  
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Table 10. Clinical chemistry 
Marker Study I II III Ctrl 
Cholesterol (mmol/L) 1.5 2.1 2.4 2.0 
Triglyceride (mmol/L) 1.3 1.5 2.0 1.2 
Creatinine (μmol/L) 10.9** 2,3 14.5 14.5 13.5 
LD (U/mL) 1.2*1 1.2*1 1.0***1 1.7 
Glucose (mmol/L) 6.1***2, **3 11.4 10.6 9.9 
HDL (mmol/L) 1.2 ND 0.8 1.1 
LDL (mmol/L) 0.15 ND 0.13 0.13 
ASAT (U/mL) 0.47*1 ND 0.6 1.1 
CK (U/mL) 11*1 ND 12 21 
AFOS (U/L) ND 85 109 64 
1) vs. Ctrl. 2) vs. II. 3) vs. III. 4) Study II vs. Ctrl. 5) Study III vs. Ctrl. LD = Lactate 
dehydrogenase HDL = high density lipoprotein, LDL = low density lipoprotein, ASAT = 
aspartate aminotransferase, CK = Creatinine kinase, AFOS = Alkaline phosphate. * (P < 
0.05), ** (P < 0.005), *** (P < 0.001). 
 
 
In study II the endothelium of several tissues was found to be positive for hVEGF-D 
in the immunohistochemical assessment (Figure 7). CD31 antibody was used to 
visualize endothelial tissue. Kidney capillaries and glomerulus, skeletal muscle 
capillaries and endothelium, liver sinusoid endothelium, brain capillaries and skin 
exhibited an intense TG expression. The endothelium in several other tissues was 
also positive for the transgene. Lymphatic capillaries were detected with LYVE-1, 
but there were no differences between the TG mice and the controls.  
 
 
Figure 7. Immunohistological stainings of TG mouse tissues in study II. hVEGF-D 
stainings of TG-negative littermate mice (a, e, i). hVEGF-D stainings of mTie1-hVEGF-D 
TG mice (b, f, j). CD31 endothelial staining of TG mice (c, g, k). Staining controls of TG 
mice without primary antibody (d, h, l). Bars 100μm. The hVEGF-D and CD31 stainings 
are from consecutive sections and with higher magnification insets to demonstrate the 
endothelial specificity of hVEGF-D 
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5.2 HINDLIMB ISCHEMIA MODEL 
It was decided to study ischemia and tissue repair in relation to VEGF-D expression 
levels, due to the angiogenic properties of VEGF-D. Hind limb ischemia was induced 
in the F1 and F2 TG mice and TG-negative littermates in studies I, II and III. One, 
two and three weeks after the procedure, the tissues were collected and analyzed in 
order to evaluate the extent of damage and regeneration. The ubiquitously expressed 
hVEGF-D significantly reduced the damage area and enhanced tissue regeneration 
(Figure 8). Tissue damage and regeneration were also assessed by morphometrical 
techniques by measuring the active regeneration areas recovering from ischemia. 
Overall between 4-15 % of the total muscle areas in TG mice had been damaged, but 
in the TG-negative controls it was substantially higher, 35-89 %. The active 
regeneration areas were generally larger in the ischemic muscle of TG mice as 
compared with the TG-negative controls. In study II, the ischemia operation 
performed on F1 and F2 TG and negative control mice had no effect on muscle 
regeneration or on the hVEGF-D mRNA expression level. The capillary number of 
skeletal muscles was counted as a way of assessing the tissue regeneration capacity, 
but no significant differences were found between the studied groups. 
hVEGF-D protein was detected with ELISA from liver and muscle extracts. Non-
ischemic F0-F3 TG mice had hVEGF-D concentrations between 120-160 pg/ml (Study 
II). The mice with ischemia displayed elevated hVEGF-D protein levels in their 
skeletal muscles, however, this increase was not significantly different from the 
levels in unoperated TG-mice. The ELISA antibody used is specific for human 
VEGF-D and should not recognize the mouse protein. 
The overexpression of hVEGF-D on vascularity was measured in intact skeletal 
muscle and myocardium by capillary staining (Figure 9). CD34 and CD31 antibodies 
were used to detect capillaries. Capillary density was increased in TG mice 
compared to TG-negative controls. No enhanced lymphangiogenesis was seen by 
LYVE-1 immunohistochemistry. A higher number of capillaries was detected in the 
intact hindlimb muscles and in myocardium in TG-positive mice compared to TG-
negative controls. 
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Figure 8. Study I, Skeletal muscle 7 days after HLI. HE-stained musculus caput 
gastrocnemius. a) TG mice showing increased regeneration with eosinophilic cytoplasm 
and internalized nuclei. Bar 200 μm. b) TG-negative littermates showing a large necrotic 
area (*). Also early regeneration shown by small basophilic myocytes (#). Bar 200 μm. 
 
Figure 9. Blood and lymphatic capillary density in VEGF-D overexpressing mice and 
negative controls shown by CD34, CD31, and LYVE-1 stainings, study I. (a) Skeletal 
muscle from a TG mouse showed increased capillary density compared to the control (b). 
As a comparison, the capillaries were stained with CD31 with similar results being seen 
(c and d). Lymphatic vessels were detected in the interstitium as well as in the venules 
and arterioles in TG mice (e) and negative controls (f) with LYVE-1. Bars in panels a-f = 
100 μm. (g) Capillaries / myocyte of intact skeletal muscle of hVEGFD TG mice and the 
TG-negative controls. (h) Capillary density in myocardium of the hVEGF-D TG-positive 
and the TG-negative littermates. Error bars represent ± SD. 
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5.3 TUMOR FORMATION 
The aging TG mice developed malignant tumors in study I; Eight tumors were 
detected, half of them being mammary adenocarcinomas. In addition, lung 
adenocarcinomas and skin carcinomas were found, but no lymphatic malignancies 
were detected. Mice produced with LV-transgenesis with the same vector backbone, 
but with a different transgene (GFP and hNrf2, nuclear factor-like 2) did not develop 
any tumors. The TG-negative littermates did not develop tumors during the follow 
up time. The mice were descendants of two founders, implying that the viral 
integration site was not the source of the tumors. Most of the mammary 
adenocarcinomas were poorly differentiated. One mouse had also metastases in the 
lungs. The hVEGF-D was expressed in the ductal surface of the tumor, not in the 
solid areas. Most tumors were actively angiogenic. Lung adenocarcinomas were 
differentiated and they displayed hVEGF-D expression in papillary and stroma of 
the papilla stalk. The anaplastic skin carcinoma showed evidence of angiogenesis 
and it was focally hVEGF-D positive. hVEGF-D mRNA was detected in all tumors. 
The mortality rates of TG mouse were increased due to these tumors (Figure 10). 
The TG-mice in study II revealed the formation of benign and malignant tumors 
in all studied generations (F0-F5), whereas the TG-negative littermates did not form 
tumors during the 25 month follow-up. The mice had originated from two founders 
indicating that the TG itself, not the integration site, was causing the tumors. 
Malignant tumors were found widely in different organs (Table 11). The general 
tumor histology from mammary gland carcinoma and hepatocellular carcinomas are 
presented in Figure 11. Benign tumors were found in the liver. Other pathological 
changes were also detected, such as cellular proliferation in kidney and spleen, 
dilated sinuses in the liver and peliosis in liver and spleen. Several metastases were 
observed and although there were vascular changes, no vascular tumors were 
detected. 
In study III a variety of tumor types also occurred not only in the KD mice, but 
also from in negative littermate controls. The tumors were benign tumors, malignant 
carcinomas and B-cell lymphomas. One anaplastic carcinoma displayed some 
necrosis and intratumoral angiogenesis, but no lymphangiogenesis. A benign skin 
angiolipoma showed CD31 positivity only in pre-existing vessels. In addition, some 
non-tumoral changes were found, such as ovarian haemorrhagic cysts and spleen 
hemosiderin deposits. Four KD mice had a staggering gait and generally were in 
poor condition, two were small in size and suffered difficulties in moving. The 
pathological findings are summarized in Table 12. 
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Figure 10. Mortality from tumors, Kaplan-Meyer curves showing the TG and KD mice 
survival in studies I, II and III as compared to negative littermate controls. 
 
 
Figure 11. General tumor histology. a) Dedifferentiated mammary gland carcinoma, 
mainly solid areas with a few luminal formations. Bar 50 μm. b) Partially necrotic 
dedifferentiated hepatocellular carcinoma. Bar 200 μm. 
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Table 11. Histopathological characterization of tumors in study II 
 
Character of the 
pathological changes 
Tissue/Organ Tumor type / Tissue change Generation 
Malignant tumors Lung Adenocarcinoma F1, F3 
 Kidney 
 
Dedifferentiated carcinoma, 
metastases in liver and pancreas 
F3 
 
 Liver 
 
Dedifferentiated hepatocellular 
carcinoma, metastases in lung 
F4 
 
 Mammary gland Dedifferentiated adenocarcinoma, 
metastases widely 
F4, F5 
 Lymph nodes Diffuse lymphoma, extranodally 
spread widely 
F5 
Benign tumors Liver Hepatoma (adenoma) F2, 
2 x F3 
 
 
Table 12. Pathological findings in study III 
 
Malignant tumors Age at death (months) Generation 
Small B-cell lymphoma   24 F2, F3 
Skin carcinoma 10 F5 
Hepatocellular carcinoma 17 F5 
Uterine and lung adenocarcinomas (Ctrl) 20 F4, F5 
Benign tumors   
Skin angiolipoma 10 F2 
Non-tumoral pathology   
Staggering and poor health 11 - 24 3 x F1, F2 
Stunted, size 1/3 of normal, difficulties in moving 0,5 - 4 2 x F1 
Haemorrhagic cyst and peliosis in spleen 24 F3 
Heart hypertrophy and calcification 24 F3 
Liver steatosis 20 - 24 2 x F5 
Focal spleen fibrosis 24 F5 
Dilated blood vessels in kidney cortex 4 F5 
Skin rashes, hairless spots (Ctrl) 7 F5 
Heart hypertrophy (Ctrl) 19 F5 
Reactive lymphoid hyperplasia (Ctrl) 16 - 18 F5 
Reactive lymphoid hyperplasia (Ctrl) 18 F5 
Edema and emphysema in lungs (Ctrl) 19 F5 
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6 Discussion 
Before VEGFs can be used in clinical therapies, it is essential to achieve a more 
profound understanding for their physiological function as well as their pathological 
properties (Yla-Herttuala 2009). VEGF-D has been mainly linked to abnormal 
angiogenesis and lymphangiogenesis, and it is believed to be involved in several 
pathological changes, such as tumor formation. Adenoviral gene transfer of VEGF-D 
has induced angiogenesis as well as vascular enlargement and permeability 
(Rissanen et al. 2003b, Anisimov et al. 2009). However, evidence for these 
involvements were not found in the KO mice, i.e. VEGF-D KO mice did not exhibit 
any clear phenotypic pattern (Baldwin et al. 2005, Haiko et al. 2008). Mice with skin 
specific expression of the full-length VEGF-D exhibited hyperplastic lymphatic 
vessels in the skin, but no angiogenesis (Veikkola et al. 2001). The present TG mouse 
models with mature hVEGF-D did display angiogenic effects, enhanced muscle 
regeneration and tumor formation. 
The lentiviral PI method was used to create TG mice. This technique proved to be 
efficient since the PI is able to bypass many of the flaws encountered with other 
traditional methods such as damage to the oocyte or inefficient transduction. In 
plasmid MI, the oocyte membrane is pierced in order to allow the transgene plasmid 
to gain access to the pronucleus. In an alternative LV-method, the zona pellucida 
protecting the oocyte is removed, which often damages the oocyte and results in a 
greater loss of embryos (Lois et al. 2002). The resulting mice are likely to be mosaic, 
since transduction is conducted at the two or four-cell stage (Singer et al. 2006). With 
direct microinjection, the transgene becomes integrated into every cell of the embryo, 
since transduction is conducted at the one-cell stage, producing genetically 
homogeneous animals. These founders are more likely to show the full phenotype 
due to gene KD or overexpression. This technique also achieves a good transgenesis 
rate and most embryos (85-100 %) survive in to the two-cell stage, whereas 
pronuclear (Gordon, Ruddle 1981) and cytoplasmic (Yang et al. 2007) injection 
methods have less (70 %) two-cell stage embryos. The LV PI-method produced a 
high number of TG founder animals, in all 79 % of the born pups were TG-positive.  
The KD method with RNAi is faster than the total KO mice, where both gene alleles 
have to be removed. It is also efficient even if there is only a single copy of the vector 
in the genome. Gene KD can be used with genes that are needed in embryonic 
development or otherwise essential.  
It was decided to determine whether the LV-mediated TG overexpression would 
endure through consecutive generations and also to determine the long-term effects 
of the transgene. Therefore TG-mice from F0 to F5 generations were examined up to 
2-years of age. In the PGK-hVEGFD mice the TG was integrated into a non-
methylated site since expression was detected over the long term and up to the F5 
generation. In the Tie1-hVEGFD mice, the TG was expressed widely in many tissues 
and the TG expression profile in tissues was similar to that found in study I. The 
similar hVEGFD mRNA expression levels may correlate with the gene function in 
different tissues. However, in the endothelial-specific model, the mRNA expression 
levels did decline in advancing generations, possibly due to site-specific methylation 
or to some other mechanism. However, the cause of this decline was not studied in 
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this thesis. In shVEGFD mice, the TG-copy numbers were low, approximately the 
same in all studied mice, so no correlation could be calculated between the copy 
number and VEGF-D expression or the pathological findings obtained. In general 
the KD mice bred poorly and the number of living KD pups was low. Some of the 
KD mice were small with a staggering gait and they had other neurological 
problems. This might be evidence of the importance of VEGF-D during embryonic 
development e.g. a low amount of VEGF-D may be harmful to the embryo with its 
deficiency being poorly compensated. Perhaps the high-copy number mice were 
aborted early and only the mice with low copy-numbers survived. The vector copy 
number and embryonic survival could correlate with functional VEGF-D protein 
levels, however, from the KD-mice VEGF-D protein was not detected with ELISA. 
Even low-copy numbers of the vector were adequate to silence the gene product to 
undetectable levels. Compensatory mechanisms may only partially substitute for the 
lack of VEGF-D. However, these results are partly in conflict with previous KO 
models that observed no major function for VEGF-D (Koch et al. 2009, Baldwin et al. 
2005, Haiko et al. 2008). This may point to a different mechanism with the present 
model, such as saturation of RNAi machinery. The VEGF-D overexpressing mice 
developed normally, they were fertile and generally healthy. This suggests that the 
transgene did not have any major effect on the developing embryo. 
LV constructs were used that produce the processed and functional form of 
hVEGF-D in TG-mice, not the full-length protein. The processed hVEGF-D binds 
almost exclusively to the angiogenic VEGFR-2, whereas the full-length and 
processed mVEGF-D binds to VEGFR-3 and thus promotes lymphangiogenesis 
(Achen et al. 1998, Baldwin 2001). In order to create a VEGF-D KD-mouse, an shRNA 
specific for both the full-length and processed forms of VEGF-D was used. These 
VEGF-D KD mice showed no effect on blood capillary density or regeneration after 
hindlimb ischemia. This supports the consept that VEGF-D in mice is mainly a 
lymphangiogenic growth factor. A study with VEGF-D KO-mice (Baldwin et al. 
2005) revealed no major effects on lymphangiogenesis or angiogenesis. This was 
explained with the minor lymphangiogenic role of VEGF-D during embryonic 
development or compensatory mechanisms. Another VEGF-D KO study did detect 
reduced peritumoral lymphangiogenesis and metastasis (Koch et al. 2009) The KD 
mice in this study had diverse problems, which may be explained at least partly by 
the disturbance of RNAi machinery. Exogenous siRNAs can stimulate immune 
responses by interferon induction, reducing siRNA activity and evoking unwanted 
side effects (Fish, Kruithof 2004, Sledz et al. 2003).  
The mature form of VEGF-D is thought to be mainly angiogenic via VEGF-R2 
(Baldwin 2001). In study I, an increased number of blood capillaries in skeletal 
muscle and myocardium was found, when comparing TG-positive and TG-negative 
littermates. In addition, regeneration after HLI was faster and injury areas smaller 
due to VEGF-D overexpression. These results are in line with previous findings 
(Rissanen et al. 2003b, Kholova et al. 2007). Acute inflammation in the ischemic 
tissue may promote the local expression of VEGFs. On the contrary, VEGF-D can 
reduce the inflammatory reaction by activating lymphatic vessels (Huggenberger et 
al. 2011). Study II did not detect any intense angiogenesis or muscle regeneration 
after HLI. This is probably because the VEGF-D is expressed only in the endothelium 
and the effective protein levels are much lower compared to those obtained in the 
ubiquitous model. The hVEGF-D protein level was slightly elevated in skeletal 
muscle after ischemia. The silencing of VEGF-D did not have any effect on blood 
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capillary density or regeneration after HLI. Therefore the role of VEGF-D in normal 
physiology remained somewhat unclear, however when overexpressed, it appeared 
to function as an angiogenic factor. The VEGF-D protein levels measured from tissue 
lysates were highest in study I (general overexpression), 4-7 times lower in study II 
(endothelial overexpression) and in study III (KD) the mVEGF-D protein was 
undetectable. The VEGF-D levels in the endothelium-specific model seemed to be 
too low to induce angiogenesis or to enhance ischemic recovery. This suggests that 
the expression of VEGF-D needs to be sufficiently high to exert a positive effect in 
ischemic tissues. In study II hVEGF-D and CD31 immunostainings were compared 
in an attempt to demonstrate the endothelial specificity of the Tie1 promoter. 
Different tissues were stained with hVEGF-D antibody for detection of the 
transgene, which was well expressed in the vascular endothelia of several tissues.  
TG-mice developed tumors upon aging, however, the tumor profiles were 
different. The ubiquitously expressed VEGF-D promoted a high proportion of 
mammary gland adenocarcinomas, but also lung and skin carcinomas were 
detected. In humans, VEGF-D overexpression has been associated with breast cancer 
and metastases (Wang, Chen & Anderson 1998, Wang et al. 2012, Zhao et al. 2012), 
which supports our results and points to a pathogenic role for VEGF-D. The 
morphology of collecting lymphatic vessels is partly modulated by VEGF-D, 
promoting metastases. This can be reduced by anti-inflammatory drugs (Karnezis et 
al. 2012). Other blood- or lymphatic vessel malignancies were not detected in this 
study. There was angiogenesis within the tumors, but no lymphangiogenesis was 
found. The TG-mice in study II showed also benign and malignant tumors in various 
organ systems, however the tumor profile was different from thath observed in 
study I. This could be explained with the endothelial expression that guides the 
VEGF-D expression to different tissues compared to the ubiquitously expressed 
model. The mice in both studies originated from two founders implying that 
perhaps the TG itself, not the integration site, was responsible for the tumors. This 
mouse strain (CD2F1) does not form tumors spontaneously (Harlan Laboratories 
2008), and therefore there has to be some other explanation. The TG or perhaps the 
LV itself could have a role in the tumorigenesis. However, in other LV-TG mice 
produced in our group, no early deaths or malignancies have been detected 
(unpublished). LVs are able to transduce several tissues in vivo, such as 
hematopoietic cells (Miyoshi et al. 1999), cardiomyocytes (Fleury et al. 2003) and 
neural cells (Naldini et al. 1996b). LV mediated gene expression is normally not 
silenced during embryonic development, which enables the use of LVs for the 
generation of TG animals (Pfeifer et al. 2002).  
LV-mediated RNAi strategies to KD genes in vitro (Abbas-Terki et al. 2002, An et 
al. 2003) and in vivo (Tiscornia et al. 2003) have been described. The hU6 promoter 
efficiently expressed shRNA and thus achieved LV-mediated gene KD. The mVEGF-
D mRNA and protein were downregulated, meaning that the silencing was done via 
the classical RNAi pathway. In addition, the immunohistological staining revealed 
that the mVEGFD was effectively silenced in different tissues. Most PolIII based 
promoters are efficient achieving a long-lasting silencing, as was shown in vitro 
(Makinen et al. 2006). However, the strong expression may saturate the RNAi 
pathway and lead to unwanted off-target effects. RNAi can also cause some toxic 
effects and activate interferon responses (Fish, Kruithof 2004, Sledz et al. 2003). U6 
vectors trigger an intense interferon response as compared to other silencing vectors. 
This could be avoided with preserving the wild-type sequence around the 
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transcription start site (Pebernard, Iggo 2004) or with regulatable vectors. The 
present LV-RNAi system did not induce any detectable interferon response in vitro 
(Makinen et al. 2006). LV-mediated RNAi is an effective technique for achieving 
gene silencing in vivo. Recently, shRNAs have been efficiently used for gene 
silencing in vitro as well as in vivo mainly in tumor models, resulting in inhibition of 
tumor survival signals (Zuo et al. 2012, Ray et al. 2012, Zhong et al. 2011). However, 
in the future, models with regulatable constructs, such as Tet on/off must be 
considered. 
The LV PI-method proved to be an efficient method for creating genetically 
modified mice. However, it is technically demanding, requires a high viral titer and 
the majority of the embryos die before birth. Study I showed that overexpressed 
VEGF-D significantly increased angiogenesis in skeletal muscles and myocardium, 
and improved muscle recovery from ischemic damage. In addition, tumor formation 
was increased, mostly mammary gland adenocarcinomas. With the right tools, 
VEGF-D overexpression could be used as a therapy for ischemic conditions, 
however, when expressed over the long-term, it may promote malignant 
transformation. Endothelially-targeted therapy could be very useful in the clinic for 
treating vascular diseases, but as shown in study II, the endothelially-targeted 
overexpression of VEGF-D did not improve tissue recovery from ischemic damage. 
However, the Tie1-promoter was able to efficiently target the expression to the 
endothelium. The shRNA-mediated KD of VEGF-D effectively silenced the target 
gene, proving the feasibility of this technique. However, the mice had a variety of 
phenotypes and the major problem might be the combination of a strong U6 
promoter and an unregulatable vector. When combined with the latest sophisticated 
tools, shRNA can be viewed as a feasible method to downregulate genes in vivo. 
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7 Conclusions 
The following conclusions were made based on the studies 
 
I The PGK-hVEGF-D TG mice showed a significantly increased angiogenesis in 
skeletal muscles and myocardium, and less muscle damage after hindlimb 
ischemic injury when compared with the TG-negative controls. However, the 
incidence of tumor formation was significantly increased in the TG mice, 
especially the development of mammary gland adenocarcinomas. 
 
II Endothelial expression of hVEGF-D revealed that targeted unregulated long-term 
expression of hVEGF-D in endothelium increased tumor frequency and 
predisposed the animals to other pathological conditions. Therefore unregulated 
expression is hazardous and can reduce the life span of TG mice. Thus 
endothelially-targeted expression does not appear to be adequate for the 
treatment of ischemic tissues. 
 
III Silencing of endogenous VEGF-D in mice caused the growth of a variety of 
tumors and other malignancies, also in control mice. These results suggest that in 
addition to actual gene silencing, some other mechanism is disturbing the normal 
physiology, such as the RNAi system.  
 
The results presented in this thesis indicate that the perivitelline injection method 
used with lentiviruses is a feasible way of creating transgenic mice. Although 
technically demanding and laborious, it is an efficient method. In the clinic VEGF-
D could be used in treatment of ischemic conditions, however, the approach must 
be made more sophisticated, targeted and controlled. In the future, the role of 
VEGFs in non-vascular cells needs to be clarified. In addition, a better 
understanding of endothelial function in vascular development and 
organogenesis could help explain the formation of several serious pathological 
conditions such as atherosclerosis and cancer. 
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Disturbances in the development 
and function of blood- or lymphatic 
vasculature are involved in many 
diseases. Vascular endothelial 
growth factors are central mediators 
in vascular development. In this 
thesis, a lentiviral perivitelline 
transgenesis method was used 
to study the role of VEGF-D in 
cardiovascular diseases, ischemic 
conditions and tumor formation. It 
clarifies the function of VEGF-D in 
angiogenesis and shows a potential 
use as a treatment in tissue ischemia. 
However, unregulated long-
term expression promoted tumor 
formation.
